公开(公告)号：EP1751113A1

公开(公告)日：2007-02-14

申请号：EP05747470.2

申请日：2005-05-11

申请人： Bristol-Myers Squibb Pharma Company

发明人： CHAO, Hannguang J. ,  TUERDI, Huji ,  HERPIN, Timothy ,  ROBERGE, Jacques Yves ,  LIU, Yalei ,  LAWRENCE, R. Michael ,  REHFUSS, Robert P. ,  CLARK, Charles G. ,  QIAO, Jennifer X. ,  GUNGOR, Timur ,  LAM, Patrick Y.S. ,  WANG, Tammy C. ,  RUEL, Rejean ,  L'HEUREUX, Alexandre L. ,  THIBEAULT, Carl ,  BOUTHILLIER, Gilles ,  SCHNUR, Dora M.

IPC分类号： C07D231/50 ,  C07D231/40 ,  C07D213/40 ,  C07D413/12 ,  C07D401/12 ,  C07D405/12 ,  C07D417/12 ,  C07D333/36 ,  A61K31/444 ,  A61P7/02

CPC分类号： C07D409/14 ,  C07C275/30 ,  C07C275/32 ,  C07D213/40 ,  C07D213/75 ,  C07D213/89 ,  C07D231/40 ,  C07D231/50 ,  C07D237/22 ,  C07D333/36 ,  C07D401/12 ,  C07D401/14 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D413/12 ,  C07D417/12 ,  C07F7/1856

摘要： The present invention provides novel pyridyl or phenyl ureas and analogues thereof, which are selective inhibitors of the human P2Y1 receptor. The invention also provides for various pharmaceutical compositions of the same and methods for treating diseases responsive to modulation of P2Y1 receptor activity.

公开(公告)号：EP1706398A1

公开(公告)日：2006-10-04

申请号：EP05711663.4

申请日：2005-01-20

申请人： Bristol-Myers Squibb Pharma Company

发明人： HERPIN, Timothy, F. ,  MORTON, George, C. ,  REHFUSS, Robert, P. ,  LAWRENCE, R., Michael ,  POSS, Michael, A. ,  ROBERGE, Jacques, Y. ,  GUNGOR, Timur

IPC分类号： C07D401/12 ,  C07D413/12 ,  C07D409/14 ,  C07D401/14 ,  C07D491/04 ,  C07D417/12 ,  C07D405/14 ,  C07D235/30 ,  C07D471/04 ,  C07D417/14 ,  C07D513/04 ,  C07D413/14 ,  C07D409/12 ,  A61K31/4184 ,  A61K31/423

CPC分类号： C07D401/12 ,  C07D235/30 ,  C07D401/14 ,  C07D405/14 ,  C07D409/12 ,  C07D409/14 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07D491/04 ,  C07D513/04

摘要： The present invention provides novel amino-benzazoles and analogues thereof, which are selective inhibitors of the human P2Y1 receptor. The invention also provides for various pharmaceutical compositions of the same and methods for treating diseases responsive to modulation of P2Y1 receptor activity.